NAD(P)H: Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 Polymorphisms in Papillary Thyroid Microcarcinoma: Correlation with Phenotype.
10.3349/ymj.2013.54.5.1158
- Author:
Junguee LEE
1
;
Koon Soon KIM
;
Min Ho LEE
;
Yeon Soo KIM
;
Min Hee LEE
;
Seong Eun LEE
;
Yong Kyung KIM
;
Min Jeong RYU
;
Soung Jung KIM
;
Min Jeong CHOI
;
Young Suk JO
Author Information
1. Department of Pathology, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Daejeon, Korea.
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
NAD(P)H:Quinone Oxidoreductase 1;
NRH:Quinone Oxidoreductase 2;
thyroid neoplasm
- MeSH:
Adult;
Carcinoma, Papillary/*genetics/pathology;
DNA Mutational Analysis;
Female;
Genetic Predisposition to Disease;
Humans;
Immunohistochemistry;
Male;
Middle Aged;
Multivariate Analysis;
Mutagenesis, Insertional;
Mutation, Missense;
NAD(P)H Dehydrogenase (Quinone)/chemistry/*genetics;
Phenotype;
Polymorphism, Genetic;
Prognosis;
Promoter Regions, Genetic;
Retrospective Studies;
Sequence Analysis, Protein;
Sequence Deletion;
Thyroid Neoplasms/*genetics/pathology
- From:Yonsei Medical Journal
2013;54(5):1158-1167
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: NAD(P)H:Quinone Oxidoreductase 1 (NQO1) C609T missense variant (NQO1*2) and 29 basepair (bp)-insertion/deletion (I29/D) polymorphism of the NRH:Quinone Oxidoreductase 2 (NQO2) gene promoter have been proposed as predictive and prognostic factors for cancer development and progression. The purpose of this study is to investigate the relationship between NQO1/NQO2 genotype and clinico-pathological features of papillary thyroid microcarcinoma (PTMC). MATERIALS AND METHODS: Genomic DNA was isolated from 243 patients; and clinical data were retrospectively analyzed. NQO1*2 and tri-allelic polymorphism of NQO2 were investigated by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) analysis. RESULTS: PTMC with NQO1*2 frequently exhibited extra-thyroidal extension as compared to PTMC with wild-type NQO1 (p=0.039). There was a significant relationship between I29/I29 homozygosity of NQO2 and lymph node metastasis (p=0.042). Multivariate analysis showed that the I29/I29 genotype was associated with an increased risk of lymph node metastasis (OR, 2.24; 95% CI, 1.10-4.56; p=0.026). CONCLUSION: NQO1*2 and I29 allele of the NQO2 are associated with aggressive clinical phenotypes of PTMC, and the I29 allele represents a putative prognostic marker for PTMC.
